FDG PET/CT Aiding in Early Diagnosis of Central Pontine Myelinolysis

Varun Singh Dhull1, Suraj Shinde, Nikhil Sane

  • 1From the Nuclear Medicine and PET/CT, Aditya Birla Memorial Hospital, Pune, Maharashtra, India.

Clinical Nuclear Medicine
|November 7, 2022
PubMed

Insights

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) aids in diagnosing central pontine myelinolysis (CPM). This imaging technique identified CPM in a patient with hyponatremia and hypokalemia when MRI was inconclusive.

Area of Science:

  • Neurology
  • Nuclear Medicine
  • Radiology

Background:

  • Central pontine myelinolysis (CPM) is a rare neurological condition.
  • Diagnosis can be challenging with conventional imaging.
  • Electrolyte imbalances like hyponatremia are often associated with CPM.

Observation:

  • A 70-year-old male presented with altered sensorium and tremors.
  • Initial laboratory tests showed hyponatremia and hypokalemia.
  • Magnetic Resonance Imaging (MRI) of the brain was unremarkable.

Findings:

  • Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) was performed to investigate potential malignancy or paraneoplastic syndrome.
  • FDG PET/CT revealed focal radiotracer uptake in the pons.
  • This uptake pattern was consistent with central pontine myelinolysis, despite the absence of CT abnormalities.

Implications:

  • FDG PET/CT can be a valuable tool for the early diagnosis of CPM.
  • This technique offers diagnostic utility when conventional imaging modalities like MRI are inconclusive.
  • Early diagnosis facilitates timely management and can improve patient outcomes.